Chugai Pharmaceutical Balance Sheet

Financials in millions JPY. Fiscal year is January - December.

Millions JPY. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	417,984	426,602	540,202	458,674	222,169	267,753
Short-Term Investments	432,111	553,094	456,143	280,308	280,938	204,217
Cash & Short-Term Investments	850,095	979,696	996,345	738,982	503,107	471,970
Cash Growth	-10.00%	-1.67%	34.83%	46.88%	6.60%	24.65%
Accounts Receivable	352,747	442,876	334,256	318,892	512,538	355,081
Other Receivables	194	236	896	1,456	1,745	928
Receivables	352,941	443,112	335,152	320,348	514,283	356,009
Inventory	288,289	276,848	240,067	273,480	292,206	208,838
Prepaid Expenses	-	24,855	23,013	21,827	18,770	17,301
Other Current Assets	48,116	16,247	11,466	11,789	8,171	9,543
Total Current Assets	1,539,441	1,740,758	1,606,043	1,366,426	1,336,537	1,063,661
Property, Plant & Equipment	481,679	479,481	441,554	420,701	386,651	352,107
Long-Term Investments	-	105,512	73,073	61,086	56,185	44,663
Other Intangible Assets	58,495	54,539	17,868	19,860	25,141	21,974
Long-Term Deferred Tax Assets	89,422	88,304	69,835	64,474	65,244	56,287
Other Long-Term Assets	96,064	1	-	-	-	2
Total Assets	2,265,101	2,468,595	2,208,373	1,932,547	1,869,758	1,538,694
Accounts Payable	107,524	127,247	65,353	112,468	209,835	152,266
Accrued Expenses	-	53,591	49,324	44,629	37,751	34,421
Current Portion of Leases	-	7,773	6,365	6,975	6,434	6,550
Current Income Taxes Payable	51,675	125,721	142,499	71,573	121,160	108,293
Current Unearned Revenue	-	37	31	31	79	86
Other Current Liabilities	168,503	96,708	26,785	52,541	48,471	25,806
Total Current Liabilities	327,702	411,077	290,357	288,217	423,730	327,422
Long-Term Leases	-	17,937	4,532	6,480	7,675	9,490
Pension & Post-Retirement Benefits	4,724	4,245	3,935	3,146	3,311	2,945
Long-Term Deferred Tax Liabilities	3,434	4,015	5,076	5,787	7,086	7,614
Other Long-Term Liabilities	21,526	5,589	2,974	3,337	3,569	3,206
Total Liabilities	357,386	442,863	306,874	306,967	445,371	350,677
Common Stock	73,202	73,202	73,202	73,202	73,202	73,202
Additional Paid-In Capital	70,694	70,515	69,896	69,355	68,806	68,223
Retained Earnings	1,763,554	1,890,042	1,746,934	1,488,738	1,293,352	1,054,050
Comprehensive Income & Other	265	-8,027	11,467	-5,715	-10,973	-7,458
Total Common Equity	1,907,715	2,025,732	1,901,499	1,625,580	1,424,387	1,188,017
Shareholders' Equity	1,907,715	2,025,732	1,901,499	1,625,580	1,424,387	1,188,017
Total Liabilities & Equity	2,265,101	2,468,595	2,208,373	1,932,547	1,869,758	1,538,694
Total Debt	-	25,710	10,897	13,455	14,109	16,040
Net Cash (Debt)	850,095	953,986	985,448	725,527	488,998	455,930
Net Cash Growth	-10.00%	-3.19%	35.83%	48.37%	7.25%	24.12%
Net Cash Per Share	516.55	579.67	598.82	440.92	297.20	277.12
Filing Date Shares Outstanding	1,646	1,646	1,646	1,645	1,645	1,644
Total Common Shares Outstanding	1,646	1,646	1,646	1,645	1,645	1,644
Working Capital	1,211,739	1,329,681	1,315,686	1,078,209	912,807	736,239
Book Value Per Share	1159.17	1230.91	1155.56	988.01	865.88	722.50
Tangible Book Value	1,849,220	1,971,193	1,883,631	1,605,720	1,399,246	1,166,043
Tangible Book Value Per Share	1123.62	1197.77	1144.70	975.94	850.59	709.13

Source: S&P Global Market Intelligence. Standard template. Financial Sources.